Law Offices of Thomas J. Lamb

  • About Our Firm
  • Drug Injury
  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Breast Implants
  • Free Case Evaluation
  • FAQs

Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots

November 7, 2019 By Law Offices of Thomas J. Lamb, P.A.

There is a new Xeljanz drug safety warning about an increased risk of blood clots resulting in pulmonary embolism (PE) and deep vein thrombosis (DVT). From this PDF document, “Xeljanz to be used with caution for all patients at high risk of blood clots”, issued in October 2019 by the European Medicines Agency (EMA), we get these details: A … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood clots, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Xeljanz

Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death

August 8, 2019 By Law Offices of Thomas J. Lamb, P.A.

This Xeljanz FDA Drug Safety Communication was issued July 26, 2019: “FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)”. From that document we get the following information: The U.S. Food and Drug Administration has approved … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood clots, Cardiovascular death, heart-related deaths, Xeljanz

Xeljanz Safety Concerns and New Precautions

August 6, 2019 By Law Offices of Thomas J. Lamb, P.A.

You may have read our previous articles about Xeljanz and its risk of leading to Pulmonary Embolism or even death.  In June, we posted "Xeljanz Related Blood Clots Can Cause Pulmonary Embolism (PE) Or Deep Vein Thrombosis (DVT) With Patient Deaths Possible" that provides information on the serious side effects found out through a post-marketing … [Read more...]

Filed Under: Unsafe Drugs Tagged With: black-box drug label warning, blood clots, Cardiovascular death, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Xeljanz

Serious Side Effects For Xeljanz 10 mg Dose Leads To European Drug Safety Regulatory Action

June 10, 2019 By Law Offices of Thomas J. Lamb, P.A.

In May 2019 there was more drug safety regulatory action, this time from Europe, regarding the serious side effects associated with Xeljanz related blood clots. We get some details from this news report, “EMA Puts Temporary Restrictions on Tofacitinib Due to PE Risk”: The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood clots, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Xeljanz

Birth Control Pills Series: Are the Current FDA Label Warnings Enough?

December 19, 2016 By Law Offices of Thomas J. Lamb, P.A.

In the previous article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz, I discussed the devastating side effects that can result from using these DRSP-containing birth control pills. For my final article in this series, I will discuss the current drug label warnings for these drugs, and contemplate whether these warnings … [Read more...]

Filed Under: Unsafe Drugs Tagged With: adverse drug effects, Bayer, Beyaz, birth control pills, birth control side effects, blood clots, drospirenone, DRSP, DVT, FDA, FDA drug label warnings, Gianvi, Ocella, PE, PMDD, PMDD treatments, Safyral, severe PMS treatments, venous thromboembolism, VTE, Yasmin, Yaz

Birth Control Pills Series: The Devastating Side Effects

December 16, 2016 By Law Offices of Thomas J. Lamb, P.A.

The first article of my blog series on Yaz, Yasmin, Ocella, Gianvi, Safyral, and Beyaz discussed how Yaz in particular was marketed to treat premenstrual dysphoric disorder (PMDD)--before PMDD was even classified as a medical condition--so that the drug manufacturer, Bayer, could increase their profits. In this article, I will provide … [Read more...]

Filed Under: Unsafe Drugs Tagged With: adverse drug effects, Bayer, Beyaz, birth control pills, birth control side effects, blood clots, Cerebrovascular Accidents, CVA, Deep Vein Thrombosis, drospirenone, DRSP, DVT, FDA, FDA drug label warnings, Gianvi, Heart Attack, Myocardial Infarction, Ocella, PE, PMDD, PMDD treatments, Pulmonary Embolism, Safyral, severe PMS treatments, Stroke, venous thromboembolism, VTE, Yasmin, Yaz

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Either way, you will get Mr. Lamb’s impressions about your case — and not that of a junior lawyer, paralegal, or (worse yet) some case-intake person.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • Drug Injury Cases
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • GenX Cancer Cases
  • Breast Implant Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • About Our Firm
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Attorney Tom Lamb

Mr. Lamb is recognized by other lawyers as practicing law at the highest level of professional experience in terms of legal ability and ethical standards — which is indicated by an AV® Preeminent™ 5.0 out of 5 rating (highest classification) rating from the Martindale-Hubbell® Lawyer Directory.

More importantly, he received the Martindale-Hubbell® Client Distinction Award, which recognizes excellence for:

Quality of Service
Overall Value
Responsiveness
Communication Ability

Read More About Tom Lamb

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma
Asbestos HUB

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2019 · Law Offices of Thomas J. Lamb, P.A.